Ligand Lifts 2026 Adjusted EPS Forecast To $9.50-$9.75 As XOMA Royalties Jump 51%
Royalty revenue rose to $70.3 million in the third quarter, while non-cash investment markdowns pushed Ligand to a $28.5 million net loss.
Ligand Pharmaceuticals, which buys and structures royalty interests in medicines developed by other drug companies, raised its 2026 adjusted earnings forecast to $9.50 to $9.75 per diluted share, from $9.00 to $9.50, after third-quarter royalty revenue climbed 51% to $70.3 million, the company said Thursday. A non-cash markdown on investments still left it with a GAAP net loss.
Royalties up, total revenue down
Royalty revenue was $70.3 million against $46.6 million a year earlier, and royalties made up 89% of total revenues and income, the company reported. Ligand credited the newly acquired XOMA assets and its key commercial royalties, including Travere Therapeutics' Filspari and Merck's Ohtuvayre.
Total revenues and income fell 32% to $78.7 million from $115.5 million. The year-ago quarter held $53.1 million of income tied to the divestiture of Pelthos; excluding it, the total rose 26%.
Revenue guidance of $270 million to $310 million was reaffirmed, with royalty revenue guided to $225 million to $250 million.
A $28.5 million loss, mostly markdowns
The GAAP net loss was $28.5 million, or $1.43 per share, against net income of $117.3 million a year earlier. The quarter included $39.5 million of pre-tax losses, among them a $35.7 million non-cash loss from changes in the fair value of equity-method and other investments.
Adjusted earnings were $2.67 per diluted share, down from $3.09. Ligand pointed to the prior-year Pelthos out-license income and higher general and administrative costs, partly offset by royalty growth.
Those costs reached $72.6 million, from $28.4 million, on transaction, integration and stock compensation tied to the XOMA deal, plus added staff.
XOMA doubles the portfolio
Ligand completed its purchase of XOMA Royalty on July 14. It added seven commercial products, including Roche's Vabysmo, and 14 late-stage programs, and the portfolio now totals more than 200 assets, the company said.
Cash and short-term investments fell to $447.4 million from $733.5 million at the end of 2025, mainly from paying for XOMA, partly offset by convertible notes due 2031. Ligand says it has about $750 million of deployable capital, counting equity investments and its credit facility.
In September it paid $23 million upfront for a royalty interest in Santen's Ryjunea and committed up to $41 million to AvenCell Therapeutics for a royalty on its pipeline.
Ligand will present an updated five-year outlook at its investor day on December 8, and the FDA's target decision date for Palvella's Qtorin rapamycin application is February 28, 2027.